Enhance.MD review: budget beyond the first-month discount

Compare Enhance’s introductory and later GLP-1 prices, then examine optional treatments and the ongoing care process.

Enhance.MD makes introductory and later prices visible for several products. That gives readers a useful starting point for a more realistic budget, as long as the first-month figure is not repeated across the entire plan.

The broader platform also promotes other therapies. This review concentrates on the GLP-1 offer and treats additional products as separate decisions that need their own clinical rationale and cost information.

Introductory price → Regular price → Optional extras. Original Planline illustration.
Three checkpoints for this report. Original illustration by Planline.

Put month two next to month one

The reviewed page listed compounded semaglutide at $112 for the first month and $212 thereafter, and tirzepatide at $180 initially and $280 thereafter. Those figures describe a promotion followed by a higher regular charge.

For a simple three-month illustration using unchanged listed rates, semaglutide would total $536 before any other applicable terms or charges. That arithmetic is not a personalized quote. Confirm the actual selected agreement, eligibility and amount due before relying on it.

Do not let a bundle obscure the prescription

Enhance’s wider offering includes other prescription wellness treatments. A bundle or program name does not establish that each component is necessary, suitable or supported by the same evidence.

Ask the clinician what each proposed product is intended to address, which evidence applies and what can be declined. The evidence guide starts with identifying the actual preparation rather than reading a broad program promise as one clinical result.

Map the care and fulfillment steps

Find out who reviews a refill, how to report tolerability concerns and which pharmacy supplies the medication. A regular monthly price should be paired with a clear description of the support available between orders.

Compounded medication is not FDA-approved. Request product-specific instructions and contact details rather than relying on the general presentation of a telehealth platform. A marketing timetable should not dictate a medical change.

How we would compare the offer

The visible first-month and later figures are helpful. We would compare the regular rate with other providers first, then show the introductory discount as a separate saving. That keeps a continuing plan from looking cheaper than its later payments.

OrderlyMeds offers another introductory-price comparison. Hims shows why a promotion may apply to membership rather than medication. Enter steady recurring charges into the Offer Timeline and note special promotional months outside its model.

One more thing to know

Can the calculator automatically apply the first-month discount?

No. Planline’s timeline assumes unchanged recurring amounts. Record the introductory adjustment separately, or use the regular price to examine the continuing payment pattern.

Source notes

Provider pages document their published offers. They do not independently establish outcomes or service performance. Article dates identify the content update; a new design does not reset an older article’s date.

  1. Enhance.MD official service information
  2. FDA: concerns with unapproved GLP-1 drugs